Humana (HUM)
(Delayed Data from NYSE)
$363.62 USD
+4.64 (1.29%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $363.77 +0.15 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum D VGM
Price, Consensus and EPS Surprise
HUM 363.62 +4.64(1.29%)
Will HUM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HUM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HUM
Humana (HUM) Q2 Earnings Beat on Medicare Advantage Strength
Compared to Estimates, Humana (HUM) Q2 Earnings: A Look at Key Metrics
HUM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Humana (HUM) Surpasses Q2 Earnings and Revenue Estimates
Can Humana (HUM) Navigate Rising Expenses in Q2 Earnings?
Insights Into Humana (HUM) Q2: Wall Street Projections for Key Metrics
Other News for HUM
Peering Into Humana's Recent Short Interest
Hummingbird Resources: Q2 Update and Growth Outlook
Chris Davis' Davis Opportunity Fund 2024 Semi-Annual Review: Looking Back
Humana’s Balanced Market Outlook and Cost Control Recovery Justify Buy Rating
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Jazz Pharmaceuticals (JAZZ) and Humana (HUM)